US FDA Initiates New Safety Review of Approved RSV Therapies for Infants
-
LN24 / 3 weeks
- 0
- 3 min read
U.S. health regulators have informed executives at Merck, Sanofi, and AstraZeneca that approved therapies for preventing respiratory syncytial virus (RSV) in infants will undergo additional safety review. The move comes amid scrutiny from individuals questioning the safety of vaccines and related therapies. The therapies—Beyfortus from Sanofi and AstraZeneca, and Enflonsia from Merck—provide infants with protective […]